Image de couverture de livre

Clinical‐data‐driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ki‐Kwang Oh, Goo‐Hyun Kwon, Jung‐A Eom, Kyeong Jin Lee, Dong Joon Kim, Ki‐Tae Suk
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	British Journal of Pharmacology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model
par: Nikita Martens, et autres
Publié: (2025)

Resolution pharmacology and the treatment of infectious diseases
par: Vivian Vasconcelos Costa, et autres
Publié: (2024)

Imperatorin ameliorates metabolic dysfunction‐associated fatty liver disease through modulating Suv39h1/Fabps/Cept1 signalling pathway
par: Yi Sun, et autres
Publié: (2025)

Clinical pharmacology in adolescent transgender medicine
par: Lauren R. Cirrincione, et autres
Publié: (2024)

Clinical pharmacology in space for astronauts and earthlings
par: Jens Jordan, et autres
Publié: (2025)

Enzyme‐responsive 612‐AYR nanoparticles for targeted inhibition of B4GALT3‐mediated ITGB1 glycosylation in hepatocellular carcinoma
par: Xiaohui Yu, et autres
Publié: (2026)

Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
par: Dai Lian, et autres
Publié: (2024)

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure
par: Sook Jin Seong, et autres
Publié: (2025)

Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling
par: Mingdian Tan, et autres
Publié: (2025)

Cannabidiol in autism: Clinical pharmacology priorities for trial design
par: Gislei Frota Aragão, et autres
Publié: (2025)

Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
par: Tahira Foyzun, et autres
Publié: (2024)

Insulin‐degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver
par: Marine Andres, et autres
Publié: (2024)

Silibinin, a commonly used therapeutic agent for non‐alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19
par: Yujie Bai, et autres
Publié: (2024)

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis
par: Andrej Belančić, et autres
Publié: (2026)

Epigenetic modifications in drug‐induced liver injury: A systematic review
par: Romina Lorena de los Santos‐Fernández, et autres
Publié: (2025)

Compound 4a induces paraptosis in liver cancer through endoplasmic reticulum stress mediated by the calreticulin protein
par: Chunmiao Wang, et autres
Publié: (2024)

Identification of new small molecules for selective inhibition of SERCA 1 in patient‐derived metastatic papillary thyroid cancer
par: Seok‐Mo Kim, et autres
Publié: (2025)

Deacetylation of BAP31 by sirtuin 2 attenuates apoptosis of hepatocytes induced by endoplasmic reticulum stress, in chronic alcoholic liver injury
par: Sai Wang, et autres
Publié: (2025)

TRPC6 suppresses liver fibrosis by inhibiting hepatic stellate cell activation via CaMK4‐CREB pathway
par: Shan Jiang, et autres
Publié: (2025)

Network‐based precision medicine and systems pharmacology
par: Arvind K. Pandey, et autres
Publié: (2025)

IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling
par: Sun‐Ae Park, et autres
Publié: (2025)

Ginsenoside Rf protects against acetaminophen‐induced liver injury by targeting CCAR2 to activate the SIRT1‐FXR signalling pathway
par: Jingjing Fan, et autres
Publié: (2026)

A systematic assessment of robustness in CNS safety pharmacology
par: Maria Reiber, et autres
Publié: (2024)

Natural product pharmacology: the British Journal of Pharmacology perspective
par: Xin Wang, et autres
Publié: (2024)

Genetic deficiency or pharmacological inhibition of cGAS–STING signalling suppresses kidney inflammation and fibrosis
par: Baihai Jiao, et autres
Publié: (2025)

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society
par: Dagan O. Lonsdale, et autres
Publié: (2026)

Drug‐induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis
par: Qingfeng He, et autres
Publié: (2024)

Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers 1
par: Andrea L. Jorgensen, et autres
Publié: (2024)

Hydroxymethylglutaryl‐CoA reductase activity is essential for mitochondrial β‐oxidation of fatty acids to prevent lethal accumulation of long‐chain acylcarnitines in the mouse liver
par: Edgars Liepinsh, et autres
Publié: (2024)

An adenosinergic positive feedback loop extends pharmacological cardioprotection duration
par: Gerald Wölkart, et autres
Publié: (2024)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
par: Alessio Funari, et autres
Publié: (2024)

Correction to “Defining and unpacking the core concepts of pharmacology: A global initiative”
Publié: (2024)

Time‐evolved metrics for safety pharmacological assessments of small molecules and biologics
par: Bharath Srinivasan
Publié: (2025)

Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review 39
par: Kira Devantier, et autres
Publié: (2024)

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms
par: Lukas Schwingshackl, et autres
Publié: (2026)

Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
par: Adrian Steulet, et autres
Publié: (2024)

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study
par: Eleanor G. Dixon, et autres
Publié: (2025)

Transient receptor potential ankyrin 1 channel modulates the abuse‐related mechanisms of methamphetamine through interaction with dopamine transporter
par: Kwang‐Hyun Hur, et autres
Publié: (2024)

The mutated cytoplasmic fragile X messenger ribonucleoprotein 1 (FMR1)‐interacting protein 2 (CYFIP2 S968F) regulates cocaine‐induced reward behaviour and plasticity in the nucleus accumbens
par: Young‐Jung Kim, et autres
Publié: (2024)

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3
par: Melissa David, et autres
Publié: (2025)